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ABSTRACT 
Fanconi anemia (FA) is a genome instability syndrome that is clinically 
manifested by bone marrow failure, congenital defects, and elevated cancer 
susceptibility. The FA pathway is known to regulate the repair of DNA 
interstrand crosslinks in part through DNA homologous recombination (HR) 
repair. Up to today 16 FA proteins have been discovered that may 
participate in the common pathway. Cells that have mutations in the FA 
genes are hypersensitive to DNA damaging agents and display chromosome 
instability. A key regulatory event in the FA pathway is monoubiquitination 
of FANCD2-FANCI heterodimer that is mediated by a multi-component E3 
ubiquitin ligase complex called FA core complex. Current model suggests 
that once the FANCD2-FANCI heterodimer is monoubiquitinated it relocates 
to chromatin where it interacts with other key repair proteins to facilitate 
DNA repair. More than 90% of the FA cases are presumed to be associated 
with defects in the monoubiquitination reaction, suggesting the significance 
of the modification in the pathogenesis of the disease. Despite the 
significance, the molecular interplay between the FA core complex and the 
FANCD2-FANCI heterodimer remains enigmatic. We are interested in the 
assembly mechanism of the various FA subcomplexes into the core complex, 
and we are actively investigating how the FANCD2-FANCI heterodimer is 
 
 
vii 
 
recruited to these putative subcomplexes. As the FA pathway is a crucial 
determinant for cellular resistance to DNA damaging agents, there have 
been hypotheses that disruption of this pathway may be beneficial in 
enhancing chemosensitivity of certain cancer cells. In collaboration with Dr. 
Cai’s chemistry lab, we will develop a screen platform to identify a small 
molecules to interrupt the monoubiquitination reaction. Completion of these 
studies will enhance the much-needed knowledge of the key enzymatic 
reaction in the pathway, and perhaps the information can be used for 
development of novel chemotherapeutic strategies.    
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CHAPTER ONE: INTRODUCTION TO UBIQUITINATION 
 
Ubiquitin as a Cellular Regulator 
Ubiquitin is a small, globular protein that has 76 amino acids that gets 
conjugated to other proteins and regulates the cell’s biological processes like 
transcription, DNA repair, protein degradation, endocytosis, inflammatory 
responses, and differentiation [1, 2]. Ubiquitin has seven lysine residues 
(K6, K11, K27, K29, K33, K48, and K63) that can be connected to each 
other in order to form a polymer. An ubiquitin polymer (polyubiquitin chain) 
is formed by the creation of an isopeptide bond in between the ε-amino 
group of an ubiquitin’s lysine and glycine 76 of another ubiquitin. 
Monoubiquitin and polyubiquitin chains are conjugated to the substrate 
protein’s lysine, specifically the ε-amino group, or to the protein’s extreme 
N-terminus [3]. Proteins that interact and recognize ubiquitin have ubiquitin 
binding domains (UBDs) within their structures [4]. There are over 20 
different UBD families, with over 200 proteins that have been discovered to 
have UBDs in their structures [5]. Ubiquitin is added to the substrate protein 
by an ATP-dependent hierarchical cascade of reactions: An ubiquitin is 
noncovalently adenylated to the C-terminus of the E1 activating enzyme as 
an ubiquitin donor, this ubiquitin is then transferred to a cysteine in the E1; 
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this second ubiquitin forms a thiol ester bond with the E1 [2]. E1 then 
transfers the ubiquitin to a cysteine residue of an E2 ubiquitin-conjugating 
enzyme, this bond is a thioester bond [2]. E2 enzymes have a UBC 
(ubiquitin conjugating) domain that is essential for the conjugation of 
ubiquitin [6]. Once the E2 is charged it interacts with an E3 protein ligase 
that is bound to the substrate to be ubiquitinated (figure 1).  
E3 ligases can belong to two different families: RING (really interesting 
new gene) E3 enzymes and HECT (homologous to the E6-AP carboxyl 
terminus) domain E3 enzymes. The RING domain contains histidine and 
Figure 1. Overview of the E1, E2, and E3 interaction for the ubiquitination of a 
substrate. Ubiquitin is added to the E1 in an ATP dependent manner. The E1 then charges 
the E2, which interacts with the E3 and ubiquitinates the substrate (Adapted from Hicke et 
al., 2005 [1]). 
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cysteine residues in specific patterns with zinc ions bound by them. The 
HECT domain has two lobes formed of approximately 350 residues. E3s that 
are from the HECT family interact with the ubiquitin charged E2 through 
their N-terminus and their catalytic site is on the C-terminus [2, 7]. In the 
human genome there are two E1 activating enzymes, over 40 E2 UBC 
enzymes, and over 600 E3 ligases [6] (figure 2).  
Polyubiquitination vs. Monoubiquitination 
A polyubiquitin chain of four ubiquitins or more on lysine 48 of a 
protein will lead to its degradation by the 26S proteasome [8]. The 26S 
proteasome contains 3 subunits: one 20S subunit and two 19S subunits. The 
20S proteasome is a hollow cylinder composed of four rings that are stacked 
on top of each other, with the active site facing the inside of the tube. The 
proteins have to be denatured before entering the chamber through a 
Figure 2. The hierarchy of the ubiquitin conjugating cascade. One E1 catalytic 
enzyme can interact and charge several E2 ubiquitin-conjugating enzymes. Each E2 enzyme 
can then interact with more E3 ligases (Adapted from Hicke et al., 2005 [1]). 
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narrow opening on the ends of the 20S proteasome [9]. To each end of the 
20S proteasome binds a 19S complex, this complex recognizes the 
polyubiquitination signal, unfolds the targeted protein, and activates the 20S 
proteasome for proteolysis [9] (Figure 3). Not every polyubiquitinated 
protein is destined to be broken down by the proteasome. It is all subject to 
the type of polyubiquitin chain, for instance polyubiquitin chains on lysine 
residue 63 can activate kinases [10]. 
Monoubiquitination is the addition of only one ubiquitin per lysine 
residue to the protein. Some proteins can be monoubiquitinated on several 
sites. One example of how monoubiquitination regulates proteins is by the 
breakdown of plasma membrane proteins that can be triggered through 
Figure 3. Protein proteolysis by the 26S proteasome after substrate 
polyubiquitination. One E1 catalytic enzyme can interact and charge several E2 ubiquitin-
conjugating enzymes. Each E2 enzyme can then interact with more E3 ligases (Adapted 
from Hicke et al., 2005 [1]). 
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monoubiquitination, for example the monoubiquitination triggers the 
endocytosis of the protein, which later gets degraded in the lysosome [11]. 
Another example is the ubiquitination on lysine residue 119 of histone H2A, 
which can change the chromosome structure and the transcription of genes 
(i.e. gene silencing) [12]. During DNA damage repair the protein 
Proliferating Cell Nuclear Antigen (PCNA) gets monoubiquitinated by the E2 
Rad6 and the RING E3 RAD18; this monoubiquitination leads to the 
recruitment of several DNA polymerases to the site of the lesion for the 
repair of the DNA [12]. Monoubiquitination of a protein can lead to different 
outcomes: changing the localization of the protein, assembly or disassembly 
of protein complexes, and altering the structure of the protein or the protein 
complex [4].  
 
Deubiquitinating Enzymes 
The addition of ubiquitin can be reversed and this process is 
dependent on deubiquitinating enzymes (DUBs). There are around 100 
known DUBs in the human genome [12]. DUBs can be categorized into five 
different families (four thiol ester proteases and a metalloprotease): the 
ovarian tumor proteases (OTUs), ubiquitin-specific proteases (USPs), the 
Josephins, ubiquitin C-terminal hydrolases (UCHs), and the zinc-dependent 
metalloproteases [12]. The role of DUBs in the cell is almost as important as 
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that of the phosphatase. DUBs can inhibit proteolysis or promote it, they can 
change the localization of a specific protein, remodel a protein’s structure, 
and even directly interact with an E3 ligase thus regulating it [13].  
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CHAPTER TWO: INTRODUCTION TO FANCONI ANEMIA AND THE 
FANCONI ANEMIA REPAIR PATHWAY 
 
Clinical Aspects and Treatment of Fanconi Anemia  
Fanconi anemia (FA) is an autosomal or X-linked genetic disorder that 
causes chromosomal instability in the cell which leads to several congenital 
defects and a high cancer incidence in FA patients. It has been estimated 
that one in 300 people are carriers of a FA mutation while the disorder itself 
is seen in one in 300,000 births [14]. Even though some patients have been 
diagnosed at 48 years old, the median age for the diagnosis of FA in girls is 
eight years and six point five in boys. In 2000, the median age for the death 
of FA patients was 30, compared to 19 in 1990. This number has probably 
increased due to medical advances which could have led to early diagnosis 
and better therapies once the disease has been confirmed [15]. A higher 
carrier frequency of 1:100 was found in Ashkenazi Jews, Afrikaaners, and 
the Romani people in Spain (gitanos) [16]. The most common congenital 
defect in FA patients is skin abnormalities (55%) followed by short stature 
(51%) even though 25% to 40% of FA patients do not have any physical 
abnormalities [15]. Bone marrow failure will usually appear during the 
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patient’s first ten years of life. 90% of FA patients have bone marrow 
problems by the time they turn 40 years old, patients with FA-
complementation group C (FANCC) mutated have the highest incidence of it. 
28% of FA patients that are 40 years old develop solid tumors, with females 
having a higher incidence of them [17]. The most prevalent cancer in FA 
patients is acute myeloid leukemia which is seen in at least 20% of FA 
patients. The risk of a FA patient to develop acute myeloid leukemia is 800-
fold higher compared to a healthy individual [18]. Other cancers that can 
affect FA patients are gynecological squamous cell carcinoma, neck and head 
squamous cell carcinoma, esophageal carcinoma. FA patients also develop 
tumors in the skin, brain, liver, and kidneys [19]. 
One of the diagnostic tests for Fanconi anemia is the chromosomal 
breakage test done with an interstrand crosslinking (ICL) agent, usually 
mitomycin C (MMC) or diepoxybutane (DEB). Cells from FA patients are 
hypersensitive to ICL agents and accrue DNA damage very fast leading to 
breaks in the chromosomes [20, 21]. Another diagnostic test for FA that is 
done in conjunction with the DEB test is the assay of the monoubiquitination 
of FANCD2 in the patient’s primary lymphocytes. If the monoubiquitination 
of FANCD2 does not occur in these cells, the transfer of FA genes by 
retroviral infection is performed, if the transcription of any of the FA proteins 
rescues the monoubiquitination of FANCD2 then the diagnosis of FA can be 
made [22].  
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Patients with FA receive androgen therapy in order to treat the bone 
marrow failure but hematopoietic stem cell transplant is the main treatment 
for bone marrow failure in FA patients, even though it does not treat the 
high cancer incidence of FA patients. The chemoradiation used in the HSCT 
can be detrimental for the FA patients due to the defective DNA repair in 
their cells so a non-irradiation immunosuppressive technique is preferred for 
the conditioning portion of the treatment [18]. Since FA patients cannot 
undergo any type of chemotherapy or radiation for the treatment of cancer 
they have to get regular check-ups in order to preclude the cancer before it 
can develop [18].  
Fanconi Anemia Pathway 
The Fanconi anemia pathway integrates different repair pathways, 
nucleotide excision repair (NER), translesion synthesis (TLS), and 
homologous recombination (HR), in order to repair and resolve these lesions 
in the cell’s DNA [23]. Up to this date there has been 16 proteins that have 
been discovered to have mutations in FA patients (FANCA, FANCB, FANCC, 
FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ, FANCL, FANCM, 
FANCN, FANCO, and FANCQ). Out of the 16 FA proteins, eight of them make 
up the FA core complex, which is activated upon DNA damage [24]. An 
overview of the proteins of the FA core complex, FANCD2, FANCI, and other 
key proteins of the FA pathway are discussed below (table 1). 
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Protein 
Other 
names 
Function in repair Source 
FANCA   Core complex; A-G-20 Subcomplex [25] 
FANCB   Core complex; B-L-100 Subcomplex [25] 
FANCC   Core complex; C-E-F Subcomplex [25] 
FANCD1 BRCA2 RAD51 interaction; homology search in HR [26] 
FANCD2   
Core complex substrate; Recruits downstream 
repair factors 
[24, 25] 
FANCE   
Core complex; C-E-F Subcomplex; interacts with 
FANCD2 
[25, 27] 
FANCF   Core complex; C-E-F Subcomplex [25] 
FANCG   Core complex; A-G-20 Subcomplex [25] 
FANCI   Core complex substrate [24, 25] 
FANCJ BRIP1 5' to 3' DNA helicase [28] 
FANCL   Core complex; E3 Ring; B-L-100 Subcomplex [25] 
UBE2T   
E2 of the FA pathway, monoubiquitinates 
FANCD2 
[29] 
FANCN PALB2 Interacts/stabilizes BRCA2 [30] 
FANCM   
Core complex; Recruits FA core complex to site 
of damage 
[25, 31] 
FAAP24   
Core complex; Recruits FA core complex to site 
of damage 
[25, 31] 
FANCO RAD51C RAD51 homologue [32] 
FANCP SLX4 
Nuclease scaffold for XPF-ERCC1 and MUS81-
EME1 
[33] 
ATR   
Phosphorylates FANCD2 and FANCI. Activates FA 
pathway 
[34] 
ATM   Phosphorylates FANCD2 after IR [35] 
BRCA1   Recruits FANCD2 to γH2AX [36] 
RAD51   Searches for homology on the sister chromatid [30] 
CtIP   
Stabilizes FANCD2; interacts with MRN complex 
and BRCA1 
[37] 
PCNA   Necessary for FANCD2 monoubiquitination [38] 
FAN1   5' flap endonuclease and 5' to 3' exonuclease [35] 
XPF-ERCC1   3' flap endonuclease; unhooks crosslinker [39] 
MUS81-EME1   Processes ICLs to DSBs [40] 
MRN 
Complex 
  
Stabilizes FANCD2 and localizes it to DNA 
damage site 
[41] 
Table 1. Summary table of the proteins involved in the Fanconi anemia pathway. 
(Adapted from Crossan et al., 2005). 
 
 
11 
 
The Fanconi Anemia Core Complex 
As stated above, eight of the 16 FA proteins (FANCA, FANCB, FANCC, 
FANCE, FANCF, FANCG, FANCL, and FANCM) and four Fanconi anemia 
associated proteins (FAAPs – FAAP16, FAAP20, FAAP24, FAAP100) form a 
core complex [25]. This core complex acts as a multi-subunit E3 ligase, with 
FANCL acting as the E3 catalytic ligase subunit. Even though the functions of 
many of the FA core complex proteins are still unknown, studies have 
suggested that there are sub-complexes within the FA core complex: 
FANCB/FANCL/FAAP100 (B-L-100) which contains the E3 ligase unit FANCL 
as previously stated, FAAP100 a 100kDa polypeptide which is thought to 
stimulate FANCL [25, 42], and FANCB whose gene resides in the X 
chromosome and gives the X-inheritance pattern to the disorder and it is 
suspected to stabilize FANCM [31, 43]; FANCA/FANCG/FAAP20 (A-G-20) 
which has been shown to bind to bind to chromatin and DNA through the 
UBZ domain of FAAP20 and  through the TPR repeats of FANCG, and FANCA 
which has been found in 66% of all of FA patients [44]; 
FANCC/FANCE/FANCF (C-E-F) which is suggested to be the sub-complex 
necessary for the physical interaction in between the FA core complex and 
FANCD2-FANCI. FANCE has been shown to be the FA core complex substrate 
adaptor and it interacts directly with FANCD2 [27], FANCC has been shown 
to be mutated in 12% of all FA patients [44] , and the N-terminus of FANCF 
has been proven to interact with the MM1 (FANCM motif 1) motif of FANCM 
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and it is suspected to act as a mediator that can interact with the other sub-
complexes making it the central connector of the FA core complex [45]. 
 
FANCM and FAAP24 
As stated previously, FANCM is also a protein of the FA core complex. 
FANCM has DNA binding activity, it specifically binds to stalled replication 
forks and as of this moment it is the only known protein in the FA core 
complex with this capability, it has been shown that FANCM can bind double-
stranded DNA (dsDNA) and single-stranded DNA (ssDNA) in vitro [45]. 
FANCM is homologous to the Hef protein (helicase-associated endonuclease 
for fork-structured DNA) and has a Superfamily 2 (SF2) helicase domain that 
is a DEAH helicase domain at its N-terminus and with FAAP24 part of the XPF 
endonuclease family. On the C-terminus FANCM contains an excision repair 
cross complementation group 4 (ERCC4) endonuclease domain [46]. The 
DEAH helicase domain is the domain that contains the ATPase activity and 
DNA binding properties of FANCM [47]. The C-terminus’ ERCC4 
endonuclease domain is actually inactive due to some amino acid variations 
in the catalytic section of FANCM’s ERCC4 compared to other proteins’ active 
ERCC4 nuclease domains [48]. It is through the C-terminus that FANCM 
interacts with FAAP24. FAAP24 (Fanconi anemia-associated protein of 
24kDa) also contains an inactive ERCC4 domain that has affinity for ssDNA 
[31]. It is speculated that together, FANCM and FAAP24, sense and 
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recognize stalled replication forks and direct the FA core complex to the site 
of DNA damage during S-phase [49]. Both of them, FANCM and FAAP24, 
contain an HhH (helix-hairpin-helix) motif in their C-terminus, this region 
being essential for the binding to DNA in a sequence-nonspecific manner 
[49].  
FANCM has been shown to be phosphorylated by ATR after DNA 
damage. The phosphorylation of FANCM intensifies its affinity to chromatin 
[50]. On the other hand, hyperphosphorylation of FANCM during mitosis that 
is induced by Plk1 leads to its inactivation, dissociation from the FA core 
complex, and degradation, which explains why there is no active FA pathway 
during mitosis [51]. After FANCM’s hyperphosphorylation event, β-TRCP 
(part of the SCF E3 ligase that is active during mitosis) recognizes FANCM 
and the serine residues of its DSGYNS sequence and triggers the 
degradation of FANCM [51]. 
Interestingly, FANCM links Bloom’s Syndrome (BS) and FA by 
interacting with RM1 and topoisomerase IIIα of the Bloom complex [45]. It 
has been shown that FANCM interacts with these proteins through its MM2 
motif, and that this motif is indispensable for its interaction with the FA core 
complex, through FANCF as it was stated previously, and the 
monoubiquitination of FANCD2 [45].   
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FANCL and UBE2T 
FANCL is another protein of the FA core complex that has a specific 
activity within the complex. FANCL acts as the E3 ubiquitin ligase of the FA 
pathway [52]. FANCL contains a RING domain at its C–terminus, it is 
through this domain that it interacts with UBE2T [6] (figure 4). The RING 
domain of FANCL contains a slight different amino acid sequence that is seen 
in most RING domains; FANCL’s RING domain has two zinc atoms that are in 
between four cysteine residues, one histidine residue, and three cysteine 
residues (compared to three cys, one his, and four cys)[6]. On the N-
Figure 4. Crystal structure of UBE2T and the RING domain of FANCL. Ribbon model 
of the crystal structure of UBE2T in blue and the RING domain of FANCL in purple which 
interacts with UBE2T. Their termini are labeled for clarification. PDB file downloaded from: 
http://www.rcsb.org/pdb/explore.do?structureId=4CCG - 3D image created with Swiss-
PdbViewer 4.1.0. 
N 
C 
C 
N 
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terminus FANCL contains three WD-40 domains that are arranged in a RWD-
like domain. The WD-40 domains have been shown to stimulate the activity 
of FANCD2 and to increase the monoubiquitination of FANCD2 [53]. UBE2T is 
the only known E2 of the FA pathway, it contains a UBC-homology domain 
that catalyzes the ubiquitination event, and its active site is Cys86 where E1 
transfers a ubiquitin molecule to [29]. UBE2T has also been shown to 
become monoubiquitinated at Lys91 this monoubiquitination serves as a 
negative auto-regulation event that inactivates UBE2T and it is enhanced by 
FANCL [29].  
 
FANCD2 and FANCI Structure 
FANCD2 is the key protein the FA pathway and its monoubiquitination 
is the main event of the FA pathway. 5% of FA patients have a FANCD2 
mutated and the incidence of a FANCI mutation is even lower [21]. Most 
studies use the monoubiquitination of FANCD2 in order to study whether the 
FA core complex is functional or not. Monoubiquitination of FANCD2 occurs 
during S-phase and after the cell has been exposed to DNA damaging agents 
like MMC, cisplatin, radiation (UV), and ionizing radiation [44]. FANCD2 and 
FANCI form a heterodimer complex that is phosphorylated by ATR (ataxia 
telangiectasia and Rad3-related) and monoubiquitinated by the FA core 
complex [34]. The crystal structure of the FANCD2-FANCI complex has been 
purified (figure 5). 
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FANCD2 has only four domains that have been discovered up to date. 
Montes de Oca et al. demonstrated that FANCD2 has a span of 24 amino 
acids at its C-terminus that is necessary for ICL repair but not 
monoubiquitination or chromatin localization after DNA damage. This 
segment is conserved in rodents and humans and it has been named EDGE 
due to the amino acid sequence within it [54]. FANCD2 also contains a PIP-
motif (PCNA-interacting protein) in its middle section [38]. It is through this 
motif that it physically interacts with PCNA, they both co-localize to the 
nucleus after DNA replication has been inhibited [38]. The PIP-motif and the 
interaction in between FANCD2 and PCNA are both necessary for the 
monoubiquitination of FANCD2 following DNA damage but not for FANCD2 
localization to chromatin, its phosphorylation by ATR, or its interaction with 
FANCE [38]. In its N-terminus FANCD2 has a CUE (coupling of ubiquitin 
conjugation to endoplasmic reticulum degradation) UBD [55]. This domain 
has been shown to be necessary for the interaction in between FANCD2 and 
FANCI and their co-localization to chromatin [55]. FANCD2’s CUE UBD 
interacts with ubiquitin on lysine523 of FANCI in a noncovalent way. This 
interaction is dispensable for the monoubiquitination of FANCD2 but it 
somehow does stabilize it and prevents it from being degraded by the 
proteasome [55]. Further down the N-terminus FANCD2 has a NLS (nuclear 
localization signal) that is necessary for the monoubiquitination of FANCD2, 
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FANCD2 and FANCI movement into the nucleus, and for the repair of ICL on 
the cell’s DNA [56] (figure 6).  
FANCD2 has been shown to have affinity for dsDNA ends and Holliday 
junctions, one of the only known biochemical properties FANCD2 has [55]. 
FANCD2 and FANCI interact with each other through a ~560 amino acid 
region along the middle of both proteins in an antiparallel manner with their 
ends remaining free [34] (figure 5). FANCD2 monoubiquitination site is 
lysine 561 and FANCI monoubiquitination site is lysine 523, interestingly 
these sites are in the interface of the two proteins but their side chains are 
still solvent exposed even though the channels are too small for UBE2T 
interaction [34]. FANCD2 and FANCI both are comprised of mainly alpha-
helices that are organized in pairs antiparallel to each other that form α-
solenoids [34]. FANCD2 and FANCI do not share homology in their whole 
structure but mainly through the solenoid segments. Solenoid 2 of both 
proteins share the most homology, this is also the segment where both 
proteins have their monoubiquitination sites [34]. It is known that the FA 
core complex and the monoubiquitination of FANCD2 are necessary for the 
monoubiquitination of FANCI but functional and monoubiquitinated FANCI is 
not necessary for FANCD2 monoubiquitination or essential for DNA repair 
[57]. What is still not known about these two proteins is whether they come 
as a heterodimer complex to the FA core complex or as separate proteins. It 
is also not known what the monoubiquitination of the proteins does to the 
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complex, it might separate or bring together the proteins, or just change the 
complex conformation, this issue is discussed in more detail further down.  
 
 
 
Figure 5. Crystal structure of the FANCD2 and FANCI complex. Ribbon model of the 
crystal structure of FANCD2 in green and the FANCI in pink. Their termini are labeled for 
clarification. PDB file downloaded from: 
http://www.rcsb.org/pdb/explore.do?structureId=3s4w - 3D image created with Swiss-
PdbViewer 4.1.0. 
N 
C 
C
N
Figure 6. Schematic depiction of the domains of FANCD2. FANCD2’s NLS is at the N-
terminus, followed by the CUE domain around amino acid 222 and the PIP box, lysine 
residue 561 that undergoes monoubiquitination is highlighted, and at the C-terminus is the 
EDGE domain (Adapted from Boisvert et al., 2014 [56]). 
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FANCD2 Regulation and Interacting Proteins 
On top of being monoubiquitinated, FANCD2 and FANCI are also 
phosphorylated. As stated before the phosphorylation of both is dependent 
on ATR [34]. FANCI contains six S/TQ motifs that are phosphorylated; two of 
the most important sites are residues serine 558 and serine 561, both of 
them are close to lysine 523 where FANCI gets monoubiquitinated [57]. The 
phosphorylation of FANCI is necessary for the monoubiquitination of FANCD2 
and its own monoubiquitination, making it a key step in activating the FA 
pathway [58]. Another key step in activating the FA pathway through 
FANCD2 monoubiquitination is the phosphorylation of FANCD2 by ATR on 
threonine 691 and serine 717 [56]. Sareen et al. have demonstrated that 
the phosphorylation of FANCI leads to the dissociation of FANCD2 and FANCI 
and that without it FANCD2 does not become monoubiquitinated nor does it 
localize to chromatin [59]. The results of Sareen’s work suggest that the 
FANCD2-FANCI complex is the inactive form of the proteins and that they 
can perform their functions in the DNA damage repair only after they have 
dissociated from each other. This model proposed by Sareen et al. would 
justify the size of the small channels that are around the ubiquitination sites 
when FANCD2 and FANCI are in a complex since the phosphorylation event 
and the dissociation of the proteins would leave the necessary lysine 
residues readily available for monoubiquitination by UBE2T [56]. 
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In addition, FANCD2 can get phosphorylated by ATM (ataxia telangiectasia 
mutated) on serine 222 in response to ionizing radiation (IR) in order to 
activate the S-phase checkpoint and it is not dependent on FANCD2 
monoubiquitination [35]. ATM phosphorylation of FANCD2 is not necessary 
for its monoubiquitination like phosphorylation by ATR is. Foci formation, and 
MMC sensitivity are also not dependent on ATM phosphorylation since ATM (-
/-) cells still see an increase of FANCD2 monoubiquitination, FANCD2 foci 
formation, and MMC resistance [35, 54].  
After FANCD2 gets monoubiquitinated by the FA core complex and 
UBE2T, it co-localizes to chromatin [54] where it interacts with several 
proteins. It is speculated that the role of FANCD2 in the DNA damage 
response is to act as a regulator and a landing pad for other downstream 
proteins. Garcia-Higuera et al. have seen co-localization of 
monoubiquitinated FANCD2 and BRCA1 (breast cancer associated 1) after 
DNA damage during S-phase [36]. The interaction of BRCA1 with 
monoubiquitinated FANCD2 is an indispensable step for the recruitment of 
FANCD2 to γH2AX [60]. H2AX gets phosphorylated on serine 139 by ATR 
when stalled replication forks form after UV damage and as a result of this, 
monoubiquitinated FANCD2 relocates to the site of damage on the chromatin 
[60].  
BRCA2 (breast cancer associated 2), known as FANCD1, also interacts 
with FANCD2 [26]. BRCA2 and FANCD2 interact through the C-terminus of 
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BRCA2, and this interaction is necessary for the co-localization of FANCD2 
and BRCA2 to chromatin, but not for the foci formation of the two proteins 
[26]. It is important to point out that the monoubiquitination of FANCD2 is 
necessary for these interactions since the interaction of the two happens 
once FANCD2 has been targeted to chromatin [26]. After BRCA2 has been 
loaded onto the chromatin with the help of FANCD2 it stabilizes the 
replication fork and it mediates RAD51 foci formation on ssDNA after DNA 
damage [61, 62]. RAD51 is a homologue of RecA that is required for 
homology directed repair (HDR), it co-localizes with BRCA2 after the cell has 
been exposed to IR and during S-phase, and with FANCD2 during S-phase 
[63]. RAD51 binds to processed ssDNA forming a nucleoprotein filament and 
searches for homology in the sister chromatid in order to repair the 
damaged DNA [30]. 
As stated before another protein that interacts with FANCD2 is PCNA, 
the details of the interaction were discussed in the previous section. It is 
important to point out though that the monoubiquitination of PCNA by 
RAD18-RAD6 on lysine 164 is necessary for the monoubiquitination of 
FANCD2, making RAD16-RAD6 another ubiquitin ligase that regulates 
FANCD2, even though in this case is in an indirect manner [56]. 
CtIP (CtBP-interacting protein) is another protein that has been shown to 
interact with FANCD2 in a BRCA1 dependent manner by Yeo et al. CtIP has 
been reported to work in a DNA damage independent manner to stabilize 
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FANCD2 [37]. CtIP has also been known to interact BRCA1 in a complex and 
with MRE11 from the MRN (MRE11/RAD50/NBS1) complex to moderate DNA 
end resection during HR and to promote HR repair [37]. FANCD2 interacts 
with CtIP on stalled replication forks and together they suppress new 
replication origins from starting and they promote the restart of the 
replication fork [37]. MRE11/RAD50/NBS1 have also been shown to interact 
with FANCD2 during S-phase, this interaction stabilizes FANCD2 and MRE11 
is crucial in the localization of FANCD2 to the DSBs [41]. 
 
Fanconi Anemia Downstream Factors 
FANCJ, also known as BRIP1 (BRCA1 interacting protein 1) is a DNA 
helicase, with 5’ to 3’ polarity, that interacts with BRCA1 during the repair of 
DSBs and it co-localizes with BRCA2 and RPA in the DNA repair structures. 
In addition, FANCJ has been shown to be a tumor suppressor protein that is 
regulated by the E2F/Rb pathway [28]. FANCJ has been shown to be 
functional in cells that lack a functional FANCD2 demonstrating that FANCJ 
acts either downstream or parallel to FANCD2 but its role in the repair of 
ICLs is not known yet.  
FANCN also termed PALB2 (partner and localizer of BRCA2) is a protein that 
interacts with BRCA2 in order to localize it to the nuclear matrix, stabilize it 
in its nuclear repair structure, and promote its activity in the nucleus for the 
repair of damaged DNA [30].   
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Fanconi Anemia Deubiquitinating Complex 
In order to inactivate FANCD2 and FANCI and to terminate the DNA 
repair FANCD2 and FANCI need to be deubiquitinated. This task is performed 
by the DUB complex USP1-UAF1 (ubiquitin-specific protease 1 and USP1-
associated protein 1) [56]. UAF1 is an activator of USP1 and it interacts with 
the SLIM (SUMO-like domain-interacting motif) of FANCI through its C-
terminus where it has two SUMO-like domains, it is believed that this 
interaction is the one that connects the USP1-UAF1 complex to FANCD2 and 
FANCI [56].  
 
Fanconi Anemia Pathway Mechanism 
Homologous recombination is one of the many mechanisms that a cell 
has in order to ensure that there is no DNA damage. HR is employed by the 
cell in order to fix DSBs, damaging deletions, and ICLs. HR is also activated 
by the cell to maintain telomeres, preserve replication forks, and during 
meiosis I chromosome segregation [64]. Since the FA pathway is used to 
repair ICLs, the focus will be on the use of mainly HR for the repair of ICLs.  
If the DNA of the cell is damaged during S-phase, FANCM and FAAP24 
together recruit the FA core complex to the site of damage [33]. The FA core 
complex and UBE2T monoubiquitinate FANCD2 and FANCI, leading to their 
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activation and localization to the chromatin, most likely they localize 
independently of each other [21]. Once activated, FANCD2 interacts with 
PCNA, BRCA2, and RAD51 as stated previously. Activated FANCD2 also 
recruits FAN1 (Fanconi anemia-associated nuclease 1), a 5’ flap 
endonuclease and an exonuclease with a 5’-3’ polarity, to the site of damage 
[35]. Another protein that is recruited by FANCD2 is FANCP (also known as 
SLX4). FANCP itself acts like a nuclease scaffold that interacts with the 
endonucleases XPF-ERCC1 and MUS81-EME1 [65].  XPF-ERCC1 is a 3’ flap 
endonuclease that unhooks the ICL from one of the strands of the replicating 
DNA strand [39]. MUS81-EME1 is a structure specific endonuclease that 
processes stalled replication forks due to ICLs into DSBs [40]. Once these 
endonucleases are recruited to the site of the ICL they unhook the cross-
linker from the template DNA strand. While the complimentary strand gets 
repaired through TLS by REV1 and Pol ζ, the leading strand, now with a 
DSB, gets repaired in a RAD51-dependent manner through HR [33]. The 
cross-linker on the complimentary strand is removed by NER. In order to 
inactivate the pathway and terminate the repair the complex USP1-UAF1 
deubiquitinates FANCD2 and FANCI [33] (figure 7).  
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Figure 7. Depiction of the removal of an ICL in a replication fork by the Fanconi 
anemia DNA repair pathway. Once a cross-linker creates the ICL FANCM and FAAP24 
recognize the lesion and recruit the FA core complex, at the same time the damage 
activates ATR to phosphorylate FANCI. Once it is recruited the FA core complex and UBE2T 
monoubiquitinate FANCD2 and FANCI. The two proteins then localize to the site of damage 
where FANCD2 recruits several endonucleases and exonucleases to remove and unhook 
the cross-linker. One of the strands is repaired by TLS polymerases. The other strand now 
has a DSB which is repaired through HR by RAD51/FANCD1 and other FA proteins 
(Adapted from Kim et al., 2012 [33]). 
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CHAPTER THREE: CO-RECRUITMENT OF THE FANCD2-FANCI 
HETERODIMER TO THE FA E3 LIGASE COMPLEX PROMOTES DNA 
REPAIR 
 
Rationale 
FANCD2 is a 1471 amino acid molecule that is involved in the key 
regulatory step of the DNA repair pathway Fanconi anemia. The FA pathway 
repairs ICLs after the cell has been exposed to cross-linking agents and 
during S-phase [55]. The activation of the FA pathway occurs when the FA 
core complex, made up of eight FA proteins and four FA associated proteins 
(FANCA, -B, -C, -E, -F, -G, -L, -M, FAAP16, -20, -24, and -100), and the E2 
enzyme UBE2T monoubiquitinates FANCD2 and FANCI; FANCD2 and FANCI 
form a heterodimer [27]. . A central regulatory event in the FA pathway is 
monoubiquitination of FANCD2 and FANCI. Monoubiquitinated FANCD2 is 
thought to trigger its association with other DNA repair proteins such as 
RAD51, BRCA1, BRCA2, FAN1, and FANCP [55]. The monoubiquitination of 
FANCD2 and FANCI is thought to be defective in more than 90% of all of FA 
cases, which shows how important this key step is in the maintenance of the 
cell’s genome through the FA pathway [27]. There is also evidence that 
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FANCD2 has monoubiquitin-independent functions, such as recruitment of 
BLM proteins to chromatin [66, 67]. FANCD2 also localizes to fragile sites of 
damaged chromosome during mitosis, although its exact function there is 
unclear [68]. Therefore the interplay between FANCD2 and the FA E3 ligase 
complex (the FA core complex) must be precisely regulated in order to 
dictate the differential functions of FANCD2. Ours and previous reports 
suggested that FANCE is the essential component of the FA core complex 
and for the FANCD2 and FANCI monoubiquitination [27]. The precise 
biochemical reactions that involve FANCE, the rest of the FA core complex, 
and FANCD2-FANCI heterodimer is yet to be elucidated. Better and precise 
understanding of this key E3-substrate reaction in the DNA repair pathway 
will contribute to the ubiquitin biology in general, as well as designing 
potential chemosensitizing strategies that can target the FA pathway in 
tumors. FANCD2 has been shown to interact with the FA core complex 
through FANCE which is part of the C-E-F subcomplex of the FA core 
complex [25, 27]. Due to the important role of FANCD2 in the repair of ICLs 
we investigated the FANCE-interaction region of FANCD2. A better 
understanding of how FANCD2 interacts with the FA core complex to be 
monoubiquitinated will help in finding the cure for FA. In addition, gaining 
insight into the regulation of the FA pathway will aid in the design of 
therapeutic treatments for cancers that have increased DNA repair 
pathways. 
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Experimental Design and Methods 
 Cell Survival Assay 
 The patient derived PD-20 cell line (a FANCD2-deficient cell line) and 
the complemented PD-20-Flag-FANCD2 cell line were seeded in triplicates in 
12-well plates. MMC was added at a final concentration ranging from 0nM to 
20nM. After the addition of MMC the cells were incubated for 7 days, and the 
surviving cells were then fixed with fixation solution (10% methanol + 10% 
glacial acetic acid) for 15 minutes. After fixation the cells were stained with 
staining solution (5 g of crystal violet dissolved in 500 mL of methanol) at 
room temperature for 10 minutes. The staining solution was then rinsed with 
deionized water and the plates were left to dry overnight. Once the plates 
were dry 300 µL of Sorenson’s buffer (14.705 g of 0.1 M sodium citrate, pH 
4.2 + 250 mL of 50% ethanol + 200 mL of nanopure water) were added to 
each well and the plates were placed on the shaker for 15 minutes. 150 µL 
from each well was then transferred to a 96-well microplate. The amount of 
purple in each well was read with a Biotek plate reader at a wavelength of 
590 nm. 
 
 Yeast Two-hybrid Analysis 
 Human FANCD2 cDNA and FANCI were cloned into Matchmaker™ GAL4 
Two-Hybrid System 3 vector PGBKT7 (Clontech) which contains the DNA-
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binding domain (DBD). Human FANCE cDNA and human FANCI cDNA were 
cloned into Matchmaker™ GAL4 Two-Hybrid System 3 vector PGADT7 
(Clontech) which contains the activation domain (AD). Site-directed 
mutagenesis of FANCD2 was achieved using pGBKT7-FANCD2 as a template 
(except the F48P-L51P double mutant, the pGBKT7-F48P-FANCD2 mutant 
was used as a template in this case) and the following primers for each point 
mutant: D19P: 5’-T AAA GAG AGC CTG ACA GAA CCT GCC TCC AAA ACC 
AGG AAG-3’, F48P: 5’-GAA AAT GAC AGC ATC CCT GTA AAG CTT CTT AAG-
3’, V49P: 5’-GAA AAT GAC AGC ATC TTT CCA AAG CTT CTT AAG ATA TCA 
GG-3’, L51P: 5’-GAC AGC ATC TTT GTA AAG CCT CTT AAG ATA TCA GG-3’, 
L51A: 5’-GAC AGC ATC TTT GTA AAG GCT CTT AAG ATA TCA GG-3’, and 
F48P-L51P: 5’-GAC AGC ATC CCT GTA AAG CCT CTT AAG ATA TCA GG-3’. 
The constructs were then transformed into the yeast strain AH109 by 
following the Small-Scale LiAc Yeast Transformation Procedure in the 
Clontech Yeast Protocols Handbook (PT3024-1). In order to select for 
transformation the transformants were plated on selection media lacking 
leucine (pGADT7) and/or tryptophan (pGBKT7), depending on which plasmid 
they were transformed with. For the interaction plates the transformants 
were spotted in triplicates in 10-fold serial dilutions on media that was 
lacking leucine, tryptophan, and histidine; this media also contained 3 mM of 
30AT and 20 µg/mL of X-α-gal. In order to check for protein expression the 
proteins were extracted from the yeast by using the TCA method described 
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in the Clontech Yeast Protocols Handbook (PT3024-1). The protein extracts 
were then run in their appropriate percentage SDS-gel and blotted with 
either DBD GAL4 antibody or AD GAL4 antibody (Santa Cruz). FANCE protein 
expression western blots were blotted with FANCE antibody courtesy of the 
Fanconi anemia Foundation. 
 
FANCD2 INTERACTS WITH FANCE THROUGH THE N-TERMINUS OF 
FANCD2 
To identify which region of FANCD2 is necessary for the interaction 
with FANCE we used the crystal structure of FANCD2 and a disorder 
probability software to plan the different truncations that would be tested in 
our yeast-two hybrid assay (figure 8). The crystal structure was taken into 
consideration in order to not disrupt a helix or a beta-sheet and to pick an 
amino acid that was conserved in several species. 
We first cloned FANCE into the pGADT7 vector and transformed it into 
our AH109 yeast strain; the expression of FANCE was then confirmed by 
Figure 8. Disorder probability diagram of FANCD2 and its secondary structure. The 
disorder probability diagram shows the disordered areas in red while the orders areas are in 
blue. The secondary structure diagram shows helices in red, coils in a gray line, and beta 
strands as yellow. Disorder probability and secondary structure diagrams were created in the 
RCSB PDB website: http://www.rcsb.org/pdb/protein/Q80V62 
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western blotting (anti-FANCE). Then we cloned full length wild-type FANCD2 
into the pGBKT7 vector and transformed it into the AD-FANCE yeast 
transformant, its expression was also confirmed by western blotting (anti-
DBD). After we confirmed that our yeast-two hybrid worked (figure 9) we 
cloned a FANCD2 truncation that was missing the last 279 amino acids 
(FANCD2-ΔC279) into the pGBKT7 vector. This truncated FANCD2 interacted 
with FANCE in our yeast-two hybrid assay thus suggesting that the C-
terminus of FANCD2 is dispensable for the interaction with FANCE (figure 9). 
In order to narrow down our search we created several more truncations 
that were cloned into the pGBKT7 vector and then transformed into the AD-
FANCE yeast transformant. Their interactions were then tested in the yeast-
two hybrid assay (figure 10).  
Figure 9. Summary of FANCD2 truncations. These truncations were engineered in 
order to test the interaction in between FANCD2 and FANCE the yeast-two hybrid assay. 
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From the results from the yeast-two hybrid assay we could determine 
that it was the N-terminus of FANCD2 that was necessary for the interaction 
with FANCE since FANCD2-ΔN51 failed to interact with FANCE and FANCD2-
ΔN26 interacted with FANCE (figure 10).   
 
Disordered Region of FANCD2 is Not Required for the FANCD2 
Interaction with FANCE 
Once we determined that the N-terminus of FANCD2 was necessary for 
the interaction of FANCD2 with FANCE we decided to change Asp19 for a 
proline residue in order to create the FANCD2-D19P point mutant. We chose 
to replace the selected amino acids with proline instead of other amino acids 
because proline is usually excluded from alpha helices and beta sheets due 
to the bulkiness of its side chain [69, 70]. We picked this specific residue 
based on a helical propensity analysis done on the disordered N-terminal 
region of FANCD2 (figure 11) [71, 72]. The logarithm that was used to 
predict the helical propensity of the region predicts three regions where a 
helix could form. Since we were interested in the disordered region Dr. 
Schmidt suggested we mutate Asp19 since it was the residue that would 
disrupt the most probable helix in the disordered region (figure 11). We then 
performed point-mutagenesis on the full wild-type FANCD2 that we had 
previously cloned into our pGBKT7 vector and cloned it into the AD-FANCE 
expressing yeast that we had previously transformed. FANCD2-D19P did 
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interact with FANCE in our yeast two hybrid system (figure 12). These 
results led us to the conclusion that FANCD2-D19P does not disrupt the 
interaction of FANCD2 with FANCE (figure 12). … 
 
...... 
..... 
 
 
Figure 10. The N-terminus of FANCD2 contains the epitope for its interaction 
with FANCE. A. FANCD2-ΔN26 and FANCD2-N502 interact with FANCD2, while 
FANCD2-ΔN51, FANCD2-ΔN238 do not in our yeast-two hybrid analysis. B. Expression 
of proteins in the transformants for the yeast-two hybrid analysis. 
 
B. 
A.
A. 
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Figure 11. Helical propensity prediction of the first 100 residue FANCD2. Graph 
depicts the helical propensity of the first 100 amino acids of FANCD2 [71, 72]. Amino 
acid Asp19 resides in the disorder region of FANCD2 and performing point mutagenesis 
and changing it to proline would disrupt this probable helix. Analysis provided by Dr. 
Kristina Schmidt, USF. 
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FANCD2 Leucine 51 is Required for the Interaction of FANCD2 and 
FANCE 
In order to find more amino acids that could be potentially necessary 
for the interaction of FANCD2 with FANCE we provided Dr. Daughdrill from 
CMMB with the crystal structure and the amino acid sequence of FANCD2. 
Dr. Daughdrill suggested that we try several amino acids in the N-terminus 
of FANCD2. From those that he suggested we selected three to mutate and 
test how they affected their interaction of FANCD2 with FANCE (figure 13). 
Just like before, the selected amino acids were changed to proline residues: 
phenylalanine 48, valine 49, and leucine 51. Since FANCD2-F48P was the 
A.
A. 
B.
A. 
Figure 12. FANCD2-D19P does not disrupt the interaction with FANCE. A. FANCD2-
D19P does not disrupt the interaction with FANCE in our two-hybrid yeast assay. FANCD2-
D19P grew just like WT-FANCD2 in the selection media. B. Expression FANCD2-D19P and 
AD-FANCE in the transformants for the yeast-two hybrid analysis. 
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first point mutant to be cloned into the pGBKT7 plasmid, we decided to also 
try a double-point mutant that was created using FANCD2-F48P as a 
template. The second residue that was mutated in the FANCD2-F48P 
construct was leucine 51. Once we confirmed the point mutations by DNA 
sequencing we transformed each one of them into the AD-FANCE yeast that 
we had previously transformed. FANCD2-F48P and FANCD2-V49P did not 
disrupt the interaction of FANCD2 with FANCE. However, FANCD2-L51P and 
FANCD2-L51P-F48P did disrupt this interaction (figure 14). These results led 
us to the conclusion that FANCD2’s leucine 51 is an indispensable amino acid 
for the interaction with FANCE. 
 
 
Figure 13. Selected amino acids for FANCD2 point-mutagenesis. Some of the amino 
acids that Dr. Daughdrill suggested to mutate. The amino acids can be seen in the N-
terminal helix of FANCD2 with the N-terminus being at the top and the growing peptide at 
the bottom of the figure. PDB downloaded from: 
http://www.rcsb.org/pdb/explore.do?structureId=3s4w - 3D image created with Swiss-
PdbViewer 4.1.0. 
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Figure 14. FANCD2-L51P and FANCD2-L51P-F48P disrupt the interaction with 
FANCE. A. FANCD2-F48P and FANCD2-V49P do not disrupt the interaction of FANCD2 
with FANCE. FANCD2-L51P and FANCD2-F48P-L51P disrupt the interaction of FANCD2 with 
FANCE B. Expression FANCD2-F48P, V49P, L51P, F48P-L51P and AD-FANCE in the 
transformants for the yeast-two hybrid analysis. 
A.
A. 
B.
A. 
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FANCD2 Point Mutants Do Not Disrupt the Interaction in Between 
FANCD2 and FANCI 
We wanted to make sure that the FANCD2 point mutants did not 
interrupt the interaction in between FANCD2 and FANCI. In order to do this 
we cloned FANCI in to the pGADT7 vector and transformed into the AH109 
yeast; we tested the expression of AD-FANCI by western blot (anti-AD). We 
then transformed the AD-FANCI expressing yeast with either wild-type 
FANCD2 or the FANCD2-F48P and FAND2-L51P point mutations. Neither 
FANCD2-F48P nor FANCD2-L51P disrupted the interaction in between FANCI 
and FANCD2 in our yeast-two hybrid assay (figure 15). These results 
suggest that leucine 51 is not necessary for the interaction in between 
FANCD2 and FANCI. 
 
Conclusion and Future Directions 
The physical and functional interplay among FANCD2, FANCI, and the 
FA core complex is still not clearly understood. Our results suggest that 
FANCD2 interacts with FANCE of the FA core complex through its N-terminus 
and that leucine 51 is critical in this interaction (figure 16 and figure 17). 
FANCD2’s leucine 51 is also conserved across species (figure 18). 
The interaction assay in yeast used here must be validated in either 
human cells using co-immunoprecipitation assay, or using purified proteins. 
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We are currently making attempts to generate purified FANCD2-FANCI 
complex, using Bac-to-Bac insect cell system. Our current work is to 
determine the effect of the mutation we found (e.g. L51P) in a relevant cell 
culture system. We are currently working to generate a FANCD2-null 
patient-derived PD-20 cell line that stably expresses wild-type and the 
mutant counterpart of FANCD2 using a lentiviral system. 
Figure 15. FANCD2-L51P and F48P do not disrupt the interaction with FANCI. A. 
FANCD2-F48P and FANCD2-L51P do not disrupt the interaction of FANCD2 with FANCI in this 
yeast-two hybrid assay. B. Expression FANCD2-F48P, L51P, and AD-FANCI in the 
transformants for the yeast-two hybrid analysis. FANCD2 runs smaller in this blot because 
FANCD2-ΔC279 was used for this yeast-two hybrid assay.  
 
B.
A. 
A.
A. 
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This complementation system can be used for validating the effects of 
mutations on FANCD2-FANCI monoubiquitination, foci formation, 
chromosome breakage rate, and cellular sensitivity to Cisplatin or MMC 
(figure 19). We hypothesize that the L51P mutant will behave as, or close to, 
FANCD2-null, based on the lack of interaction with FANCE. However there is 
a possibility that it is not the case; L51P mutant may rescue the FANCD2 null 
phenotype only to a certain degree. This outcome would suggest that 
FANCD2 clearly has functions independently of its interaction with FANCE 
and possibly with the FA core complex. Indeed, recruitment of BLM protein 
to chromatin is mediated by FANCD2, but it may be independent of its 
monoubiquitination status [66, 67]. In addition, a series of three papers 
recently suggested that FANCD2 has a role in recruiting CtIP, an 
exonuclease that plays essential role in DNA double strand end resection 
during the HR repair; however, there appears to be a conflicting information 
as to whether monoubiquitination is essential for this process. Our 
complementation system may be able to dissect the functions of the FANCD2 
monoubiquitination that contribute to the field.  
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Figure 16. Proposed model of the interaction in between FANCD2 and FANCE of 
the FA core complex. FANCD2 interacts with FANCE through its N-terminus and residue 
leucine 51 is critical for this interaction. This interaction then leads to the 
monoubiquitination of FANCD2 by UBE2T and the recruitment of downstream DNA repair 
factors.  
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B.
A. 
A. 
Figure 17. Leucine 51 of FANCD2 in the crystal structure of the FANCD2-FANCI 
complex. A. Crystal structure of FANCD2 in pink and FANCI in pink. The N-terminus of 
FANCD2 can be seen in blue with leucine 51 highlighted in red. B. A close-up of the 
structure of the N-terminus of FANCD2 with leucine 51 highlighted in red. PDB 
downloaded from: http://www.rcsb.org/pdb/explore.do?structureId=3s4w - 3D image 
created with Swiss-PdbViewer 4.1.0. 
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Figure 18. Leucine 51 is conserved across species. Aligned sequences of the first 60 
amino acids of FANCD2 of Homo sapiens (human), Mus musculus (mouse), Sus scrofa 
(pig), Gallus gallus (chicken), and Xenopus laevis (frog). Leucine 51 is marked by two red 
arrows at the top and at the bottom. Sequences aligned using Clustal Omega 
http://www.ebi.ac.uk/Tools/msa/clustalo/. 
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Figure 19. PD-20 cell line is sensitive to the cross-linker MMC while PD-20 
complemented with WT FANCD2 is not. A. Colony formation on the plate after PD-20 
and PD-20+FANCD2 have been treated with MMC for 7 days. Colonies form and grow in 
the well that have PD-20+FANCD2 but not in the well with PD-20 cells. B. Graph depicting 
the percentage of the cells that survived the MMC treatment. PD-20 cell survival drops at 
10 nM of MMC. 
B.
A. 
A. 
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CHAPTER FOUR: INHIBITION OF UBE2T BY SMALL PEPTIDES 
 
Rationale 
The FA pathway regulates DNA repair in order to maintain genome 
stability. The FA pathway is seen to be highly active in rapidly proliferating 
tissue. 11 proteins from the FA pathway have increased mRNA levels in brain 
tumors when compared to normal brain tissue [73]. Even though the FA 
pathway has an important role in the cell’s genome integrity and it has been 
seen to be upregulated in cancer cells, no specific inhibitor of the FA 
pathway has been reported yet. An inhibitor of CDK1, which phosphorylates 
BRCA1, has been shown to inhibit HR and make cells sensitive to the 
chemotherapy treatment; this CDK1 inhibitor is still not specific enough in 
order to be utilized as a therapeutic agent for cancer patients [74]. Cisplatin 
is a commonly used chemotherapy drug, many cancers will become 
resistance to cisplatin treatment. This resistance could be in part due to 
upregulation the FA pathway, which is required to repair cross-links in the 
cell and is highly active in cancer cells (figure 7, p.24-25) [75].  
UBE2T is the E2 conjugating enzyme of the FA pathway and it binds to 
FANCL, the E3 ligase unit of the FA core complex [53]. Cells that do not 
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express UBE2T are sensitive to DNA damaging agents, which leads to 
chromosomal breaks and genome instability [29]. The monoubiquitination of 
FANCD2 by UBE2T is the key regulatory step of the FA pathway, if this 
crucial step can be inhibited cells can become sensitive to cross-linking 
agents like cisplatin [29]. We are currently studying the inhibition of UBE2T 
by small peptides and its effect on the monoubiquitination of FANCD2. Dr. 
Cai from the USF Chemistry department has previously found a γ-AApeptide 
that inhibits STAT3’s interaction with DNA in cultured cells at a concentration 
of 100 µM [76]. Using the same approach Dr. Cai provided us with peptides 
that were designed to mimic the interphase in between UBE2T and FANCL 
and in addition, he provided us peptides that have been picked from a 
library and have been shown to interact with UBE2T in their initial UBE2T 
interaction screen. 
Experimental Design and Methods 
GST Protein Purification 
 BL21 bacteria that had been transformed with pGEX-6P-1 expressing 
the desired proteins (either FANCL-RING, UBE2T, or no protein) (GE 
Healthcare) was inoculated in 50mL of media overnight at 37°C. The next 
morning 250 mL of media was added to the culture. The culture was left to 
incubate for two hours at 37°C. IPTG was then added to the culture to a final 
concentration of 300µM and the culture was incubated for two more hours. 
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The culture was spun at 5,000 rpm for seven minutes. The supernatant was 
discarded. The pellet was re-suspended in GST buffer (150 mM NaCl, 20 mM 
Tris pH 7.4, 0.5% triton, 0.1% EDTA) and sonicated (01, 01, 50%) for one 
minute, the homogenate was then spun down at 20,000 rpm for 40 minutes. 
The supernatant was incubated with 100 µL of glutathione beads (Sigma 
Aldrich) overnight. The beads were washed with GST buffer four times and 
the purified proteins were then ran in a SDS page gel and stained with 
coomassie dye. In the case of UBE2T, the GST tag was then cleaved by 
washing the beads with cleavage buffer (1 M tris pH 8, 5 M NaCl, 500 mM 
EDTA, 1 M DTT, and 10% NP-40) and then incubating PreScission Protease 
(GE Healthcare) overnight. The beads were then spun down and the 
supernatant was collected. The purified UBE2T was then confirmed by 
running it on a SDS gel and staining with coomassie. The amount of UBE2T 
was then assessed by constructing a standard curve. 
 Screening of Small Peptides 
 Dr. Cai’s lab from the Chemistry Department at USF has synthesized 
and provided to us several γ-AApeptides, which contain N-acylates-N-
aminoethyl amino acid units (figure 20) and are resistant to proteolytic 
degradation [76]. Dr. Cai acquired a peptide library which was incubated 
with purified UBE2T that we provided for him. After this incubation, the 
beads were incubated with UBE2T antibody (Bethyl labs). Next the beads 
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were incubated with Alexa Fluor 594 secondary antibody. Fluorescent beads 
were then selected under a microscope. The peptides were cleaved off from 
the beads, sequenced, and synthesized. Once we acquired the peptides we 
dissolved in water to a final concentration of 6 mM.  
 GST Pulldown 
 Once the GST proteins were purified (see method above), purified 
UBE2T was incubated with either GST-FANCL-RING or GST in binding buffer 
(50 mM NaCl, 10 mM Tris pH 7, and 0.25% NP-40) for four hours. The beads 
were then washed with the binding buffer four times. 2X Laemmli buffer was 
then added to the beads and they were boiled for 3 minutes. The 
supernatant was run in a SDS gel. The membranes were then blotted with 
UBE2T antibody (Bethyl labs).  
In Vitro E2 Charging Assay 
 The E2 charging assay was performed by adding 500 nM of E1 
(BostonBiochem), 10 µM of His-ubiquitin (Sigma Aldrich), and 0.8µM of 
Figure 20. Structure of a γ-AA peptide. (Adapted from Teng, et al., 2014 (73).  
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UBE2T in reaction buffer (10 mM NaCl, 2 mM ATP, 10 mM tris pH 7.5, 1 mM 
MgCl2, 0.1 mM DTT). This reaction was then incubated at room temperature 
for 45 minutes. The tubes then got added either 2X Laemmli buffer without 
β-mercaptoethanol or Laemmli buffer with β-mercaptoethanol. The tubes 
that contained β-mercaptoethanol were boiled for 3 minutes. The reaction 
was then ran on a SDS gel. The membranes were blotted with ubiquitin 
antibody (Millipore) and UBE2T antibody (Bethyl labs).   
In Vivo FANCD2 monoubiquitination assay 
HeLa cells were plated in a 6-well plate, once the cells reached a 70% 
confluency the peptide inhibitors were added in different concentrations. The 
next morning the media was removed and the cells were treated with 30 µJ ▪ 
m−2 UV irradiation. The media was added back on and the cells were 
harvested five hours later. The cell extracts were ran on a SDS gel and 
blotted for FANCD2 (Santa Cruz).  
GST-FANCL-RING Pulls Down UBE2T In Vitro 
We purified UBE2T by GST purification and PreScission protease 
cleavage and the RING structure of FANCL by GST purification (figure 21). 
GST-FANCL-RING and GST were incubated separately with UBE2T in order to 
establish the interaction in between GST-FANCL-RING and UBE2T.  
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We did see an enrichment in the interaction in between UBE2T and GST-
FANCL-RING in vitro but not in between GST and UBE2T (figure 22). These 
results show us that just the RING domain of FANCL is necessary for the 
interaction with UBE2T in vitro and it gives us a good in vitro assay to test 
the interaction of the proteins.  
 
Two Peptides Inhibit FANCD2 Monoubiquitination In Vivo 
We wanted to test whether the peptides that we acquired from Dr. 
Cai’s lab inhibited the monoubiquitination of FANCD2 in vivo. HeLa cells were 
treated with the peptides for 16-17 hours. Afterwards the cells were 
damaged with UV irradiation. Inhibition of the monoubiquitination of FANCD2 
was seen with peptide 1 (i-1) and peptide 2 (i-2), but not with the others 
(figure 23, panel A, lanes 5 and 8). It is important to note that these two 
Figure 21. Purified GST, GST-FANCL-RING, and UBE2T. A. Coomassie stained gel 
shows the purified GST and GST-FANCL-RING. B. Coomassie stained gel shows the 
purified GST-UBE2T and the GST cleaved UBE2T. 
BA
 
 
52 
 
peptides are the same molecular formula, peptides 2 (i-2) is the circular 
conformation of peptide 1 (i-1) (figure 24).  
UBE2T is Ubiquitinated In Vitro but Not Inhibited by the Peptides 
Once we established which inhibitors inhibited the monoubiquitination 
of FANCD2 in vivo, we wanted to see if it was the UBE2T ubiquitin charging 
step that was being inhibited by the two peptides that showed inhibition of 
FANCD2 in our in vivo assay. We first set up the in vitro UBE2T charging 
Figure 22. UBE2T interacts with GST-FANCL-RING in vitro. A. GST blot showing GST 
and GST-FANCL-RING purified proteins in the GST pull down reactions B. UBE2T protein is 
enriched in the reaction incubated with GST-FANCL-RING. C. Coomassie stained gel of 
UBE2T that was added to the pull down reactions. 
A. B. 
C. 
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assay and made sure that it worked properly (figure 25). Human purified E1 
and UBE2T were incubated in the presence of ATP and ubiquitin for 45 
minutes at room temperature. The results showed that both E1 and UBE2T 
were ubiquitinated in vitro. Reducing the reactions by the addition of 2X 
laemmli buffer with β-mercaptoethanol and 3 minutes of boiling removed the 
ubiquitin that is bound on the E1 by a thiol ester bond (figure 26). Once the 
E2 charging assay was confirmed to work by repeating, we repeated the 
reactions but added different concentrations (10 µM, 50 µM, 100 µM, or 150 
µM) of i-1 or i-2. Neither i-1 nor i-2 inhibited the ubiquitin charging of 
Figure 23. i-1 and i-2 peptides inhibit the monoubiquitination of FANCD2 in 
vivo. A. The monoubiquitination of FANCD2 is only inhibited by i-1 and i-2 but not by 
the rest of the provided inhibitors. B. FANCD2 monoubiquitination with and without 
damage without any inhibitor. C, E, D. Inhibitors 3 through 5 do not inhibit FANCD2 
monoubiquitination. 
µM 
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UBE2T. These results lead us to the conclusion that these two inhibitors do 
not disrupt the first step of the FA ubiquitin cascade.  
Conclusion and Future Directions 
UBE2T is located in 1q32.1, a region of chromosome one that has been 
shown to be amplified in many cancers. Since UBE2T is essential for the 
monoubiquitination of FANCD2 its inhibition in some cancers would, in 
theory, be a valid combination-therapy for tumors that have acquired 
cisplatin resistance. Despite the recognition of the FA pathway as a 
therapeutic target, no specific FA pathway inhibitors have been developed up 
to date [75].  
Our study was conceptualized and designed with the goal that isolating 
a specific inhibitor of the UBE2T-FANCL interaction would: 1) provide a 
proof-of-principle that the critical E2-E3 reaction in the FA pathway can be a 
Figure 24. Molecular structure of i-1 and i-2 peptides. The red asterisk in i-
2 depicts where the molecule was linearized. 
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valid therapeutic target, 2) provide a useful pharmacologic tool that allows 
‘acute’ inhibition of the FA pathway. For the latter point, current methods of 
disrupting the FA pathway in cultured cells rely on RNAi-mediated 
knockdown or, more recently, genome-editing knockout technology, which 
often hampers researchers to investigate more direct functions of the FA 
proteins that are independent of other changes associated with when the 
gene is depleted (e.g. cell cycle).  
Although our current effort so far was unsuccessful in identifying an 
inhibitory peptide, we will continue to screen potential peptido-mimetics that 
can specifically disrupt the UBE2T-FANCL interaction. We will need to further 
optimize our assay condition that measures the interaction between UBE2T 
and FANCL, in order to test the efficacy of these inhibitors in vitro. We may 
further expand our efforts to screen for peptide inhibitors of the FANCE-
FANCD2 interaction, once we are able to purify large amounts of these 
recombinant proteins that can be used for the peptide-selection procedures. 
Our interaction analysis of FANCE-FANCD2 suggests that the FANCE-binding 
surface of FANCD2 may not be an extensive flat-surface, but rather a small 
hot spot within a helical area that may be sufficient for binding. This 
possibility must be more rigorously tested with structural analysis of the two 
purified proteins together; however, this can be a daunting task due to the 
very low affinity between the two proteins. 
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In order for the peptide-mimetic based inhibitor approach to be 
successful, a few technical improvements have to be made; at this point we 
have no way of determining that these peptide-mimetics are successfully 
entering the cytoplasm and nucleus of the cultured cells, where they can 
interact with their target proteins. Lipid-based delivery system can be 
adapted for more efficient delivery of these peptides. 
Consistent with previous reports we have established that UBE2T and 
the RING domain of FANCL interact in vitro and that UBE2T gets charged 
with ubiquitin in vitro [29]. Our in vitro ubiquitination and GST pulldown 
assay will allow us to evaluate the efficacy of the small peptides selected in 
Dr. Cai’s laboratory. We found that two of them, i-1 and i-2, inhibit the 
monoubiquitination of FANCD2 in vivo. We are currently trying to set up and 
optimize the GST-FANCL-RING pulldown assay in order to determine 
whether the inhibitors disrupt the interaction between UBE2T and the RING 
domain of FANCL (figure 27) in vitro.  
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B.
A. 
A. 
Figure 25. UBE2T gets ubiquitinated in vitro. A. Anti-ubiquitin blot showing E1 
ubiquitination in not reduced samples. The ubiquitination of UBE2T can be seen in 
both figures. B. Ubiquitination of UBE2T can be seen by UBE2T blotting in the 
reactions that contain all the needed components. Both red asterisks represent non-
specific bands. 
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Figure 26. Inhibitors do not disrupt UBE2T charging.  Anti-UBE2T blot shows that 
the inhibitors do not disrupt the ubiquitination of UBE2T in vitro. Red asterisk indicates a 
non-specific band. 
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Figure 27. i-1 and i-2 might inhibit UBE2T-FANCL interaction. The inhibitors 
provided by Dr. Cai might inhibit the interaction in between FANCL and UBE2T which 
leads to the inhibition of the monoubiquitination of FANCD2 in vivo. 
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